title: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
abstract: Thirty-four patients with chronic myelogenous leukemia in chronic phase were treated with busulfan 16 mg/kg and cyclophosphamide 120 or 200 mg/kg before allogeneic bone marrow transplantation from an HLA-identical sibling. Cyclosporine, methotrexate and prednisone were used for graft-versus-host disease (GVHD) prophylaxis. The actuarial probabilities of survival and relapse-free survival at 82 months were 71%. With a maximum follow-up of 2471 days, none of the patient experienced hematologic or clinical relapse. In one patient reappearance of host cells was documented 180 days post-transplant which disappeared 277 days post-transplant and the patient is in complete hematological and cytogenetic remission 5 years after the transplant. The probability of transplant-related mortality was 29% while the probability of moderate to severe acute graft-versus-host disease was 38%. This study indicates that busulfan and cyclophosphamide are a good conditioning regimen for marrow transplantation in patients with chronic myeloid leukemia in chronic phase.
authors.affiliation: Divisione di Ematologia, Ospedale di Pesaro, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Galimberti
authors.forename: P
authors.initials: P
authors.lastname: Polchi
authors.forename: G
authors.initials: G
authors.lastname: Lucarelli
authors.forename: E
authors.initials: E
authors.lastname: Angelucci
authors.forename: D
authors.initials: D
authors.lastname: Baronciani
authors.forename: C
authors.initials: C
authors.lastname: Giardini
authors.forename: D
authors.initials: D
authors.lastname: Gaziev
authors.forename: B
authors.initials: B
authors.lastname: Erer
authors.forename: M
authors.initials: M
authors.lastname: Ripalti
authors.forename: S
authors.initials: S
authors.lastname: Rapa
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002066:Busulfan / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D014184:Transplantation, Homologous
chemical_list: D016572:Cyclosporine; D003520:Cyclophosphamide; D011239:Prednisolone; D002066:Busulfan; D008727:Methotrexate